ALZHEIMER’S DISEASE DIAGNOSTICS AND THERAPEUTICS MARKET ANALYSIS

Alzheimer’s Disease Diagnostics and Therapeutics MarketSize and Trends

Global Alzheimer’s disease diagnostics and therapeutics market is estimated to be valued at US$ 6,231.1million in 2022 and is expected to exhibit a CAGR of 5.4% during the forecast period (2022-2030).

Global Alzheimer’s disease Diagnostics and Therapeutics Market- Drivers

Increase in the prevalence of Alzheimer’s disease in the old age population is expected to drive the market for the forecast period.

According to Alzheimer's Association, April 2022, an estimated 6.5 million people age 65 and older in 2021 were living with Alzheimer's in the U.S. among which 73% were aged 75 or older.

Key players are focusing on providing new diagnostic tests which will drive the market growth during the forecast period. For instance, Attyloid GmbH, a biotechnology company, offers a biomarker-based laboratory test sFIDA (surface-based fluorescence intensity distribution analysis), for diagnosing Alzheimer’s disease. sFIDA can identify and quantify Aβ oligomers. These small protein aggregates play a significant role in the development and prognosis of Alzheimer’s disease. By sFIDA, differentiation between control samples and AD patient is easily possible.

Global Alzheimer’s disease Diagnostics and Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another.

The rising cases of COVID-19 are expected to have a short-term negative impact on diagnostic rates of Alzheimer's disease. The short-term effects on the market are less prominent; however, the adverse impacts of COVID-19 on the global economy can have significant effects on the market.